|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期2003-03-04 |
靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1993-01-01 |
靶点- |
作用机制- |
|
|
|
非在研适应症- |
最高研发阶段临床前 |
首次获批国家/地区- |
首次获批日期- |
An Open-Label Phase I/IIa Study to Assess the Safety and Tolerability Profile of TR399 in Healthy Volunteers and Erectile Dysfunction Patients
The purpose of this phase I/IIa study is to assess the safety and tolerability profile of TR399 in healthy volunteers and erectile dysfunction patients. This study will be conducted via a single-arm and open-label fashion.
100 项与 Tritech Biopharmaceuticals Co., Ltd. 相关的临床结果
0 项与 Tritech Biopharmaceuticals Co., Ltd. 相关的专利(医药)
100 项与 Tritech Biopharmaceuticals Co., Ltd. 相关的药物交易
100 项与 Tritech Biopharmaceuticals Co., Ltd. 相关的转化医学